Detalhe da pesquisa
1.
Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study.
Haematologica
; 109(1): 209-219, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37439343
2.
Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome.
Invest New Drugs
; 41(2): 350-355, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37004644
3.
A first in man study to evaluate the safety, pharmacokinetics and pharmacodynamics of RP7214, a dihydroorotate dehydrogenase inhibitor in healthy subjects.
Br J Clin Pharmacol
; 89(3): 1127-1138, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36217901
4.
A first-in-human study to evaluate the safety, tolerability and pharmacokinetics of RP3128, an oral calcium release-activated calcium (CRAC) channel modulator in healthy volunteers.
J Clin Pharm Ther
; 46(3): 677-687, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33314326
5.
Observations on healthcare workers & SARS-CoV-2 infection.
Indian J Med Res
; 152(1 & 2): 137-138, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32773418
6.
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study.
Clin Lymphoma Myeloma Leuk
; 20(2): 78-86, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31761713
7.
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma.
Cancers (Basel)
; 12(8)2020 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32824175